In 2006, induced pluripotent stem cells (iPSCs) were first introduced by Shinya Yamanaka at Kyoto University in Japan. Yamanaka’s discovery, which earned him the Nobel prize in 2012, enabled the use of human cells in stem cell science, bypassing the use of embryonic stem cells (ESCs). As a result of this advance, one of the most important applications for induced pluripotent stem cells has become their use as predictive technologies to support and streamline drug safety testing. [Read more…]
Awards Given to Induced Pluripotent Stem Cell (iPSC) Researchers
Since induced pluripotent stem cells (iPSCs) were first produced in 2006 from mouse cells and in 2007 from human cells, research scientists have recognized the wide-ranging potential of the cell type, including the possibility of using them in drug and toxicology screening, disease modeling, and cellular therapy applications ranging from gene correction, to whole tissue regeneration, individualized medicine, and more.
Since the discovery of iPSCs, the commercial sector has also recognized the huge profits that could potentially be generated from the cell type, and the question being explored among the private sector has been how to generate maximal commercial value through the development of iPSC applications and technologies.
Axiogenesis to Host “iPSC Derived Cells & Assays Come of Age” User Symposium on June 13 in Boston, Massachusetts
Scheduled for June 13, 2016, in Boston, Massachusetts, Axiogenesis is hosting an American symposium titled, “iPSC Derived Cells & Assays Come of Age.” Hosted at the Westin Waterfront, the symposium will explore how experts in the pharmaceutical industry and leading academic institutions are using Axiogenesis’ cells and assays in drug discovery, safety/toxicology screening, and bioengineering. It will also present current approaches to establish and define standards for these cellular models.
Expected to be widely attended by representatives from the pharmaceutical sector, symposium attendees will also view case studies of iPS cells in drug development decision-making and biomedical research. [Read more…]
ORIG3N Opens Laboratory and Expanded Headquarters to Support World’s Largest Crowdsourced Biorepository of iPSCs
In major news released today, ORIG3N announced that it has opened a new regenerative medicine laboratory and expanded headquarters in Boston.
Founded in 2014, ORIG3N is creating the world’s largest crowdsourced biorepository of induced pluripotent stem cells (iPSCs) called LifeCapsule™. It uses these blood cells to produce patient-specific iPSCs to grow different cell types, including heart cells (cardiomyocytes), liver cells (hepatocytes), brain cells (neurons), and more.
In addition to collecting donated blood samples for iPSC production, ORIG3N offers an optional LifeCapsule membership, in which individuals can pay $99/year to get permanent access to their own immortalized iPS cells. ORIG3N also has two other business units, LifeProfile and LifeSystems, which are discussed in detail in the interview below.
Learn more by reading the full press release below, printed with permission from Julie Hall, Managing Director of Havas Health and media contact for ORIG3N. [Read more…]
European Bank for iPS Cells Launches Cells for Disease Modelling and Preclinical Research
Recently the European Bank for induced pluripotent Stem Cells (EBiSC) announced the launch of its on-line catalogue of iPSCs for use in disease modeling and pre-clinical research. The cell lines were created and deposited by EBiSC partner labs and a broad range of external organisations.
Upcoming efforts will introduce to the bank a large number of Parkinson’s and Alzheimer’s Disease lines, as well as lines for diabetes, cardiovascular research, muscular dystrophies, neuropathic pain, and more. These new lines will be produced through external collaborations, as well as cell line creation within the EBiSC.
Specifically, EBiSC announced: [Read more…]
- « Previous Page
- 1
- …
- 14
- 15
- 16
- 17
- 18
- 19
- Next Page »